Acadia Pharma (ACAD) Tops Q3 EPS by 5c, Beats on Revenue, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- Tesla acquires AI hardware company for up to $2 billion in stock
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
Acadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview
November 2, 2023 4:05 PM EDT- Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise
- 3Q23 DAYBUE (trofinetide) net product sales of $66.9 million
- 3Q23 NUPLAZID® (pimavanserin) net product sales of $144.8 million
SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2023.
In the third quarter, Acadia delivered record product revenue, underscoring the continued strong launch of DAYBUE for the treatment of Rett syndrome, and market share growth for the... More
